Panthera leads the way in the UK with specialist research sites for NASH and NAFLD studies
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis NASH and Non-Alcoholic Fatty liver Disease NAFLD have no approved medical treatments to treat these inflammatory conditions.
Panthera is already involved with two trials with several more in the pipeline.
There are over a thousand studies1 underway into these conditions across the world with more than ten pharmas having research programs in various stages of clinical development. However, because patients have few or no symptoms, until the conditions become a serious threat to health, finding NASH and NAFLD patients requires specialist services to undertake the blood tests, biopsies, and scans needed to accurately detect the disease.
With specialist sites in in Preston, Manchester, London, and Glasgow Panthera has built the capability to undertake the mass screening necessary to identify and enrol patients who 95% of the time will not know they have the condition.
Stuart Young CEO of Panthera commented “We were approached some time ago to help identify these patients as there was little capacity in the UK to do so. Since then we have developed a network of experienced hepatologists and the clinical support infrastructure to be able to find the patients and the expertise to run these trials.”
Panthera as well running trials in primary care conditions is now a world leader in running specialist clinical trials in Neurology, Oncology – in partnership with Rutherford Cancer centres – and NASH and NAFLD.
Patients who are particularly at risk of developing NASH and NAFLD are those patients who have diabetes, metabolic syndrome and are overweight. It is thought that several million patients across the UK could be developing these conditions. Presently the only treatment is gradually reducing weight, making healthy food choices and regular exercise.
Notes to editors
About Panthera Biopartners – an Independent Site Management Organisation
Panthera Biopartners was founded by Dr Ian Smith – founder of Synexus - and Professor John Lyon – previously senior executive in Covance and serial entrepreneur - to provide CROs and pharma clients with services relating to the recruitment and running of clinical trials at customised clinical trial sites by GCP trained healthcare professionals.
Panthera has a growing network of sites across the UK managing studies in a variety of conditions in both primary care settings and hospital sites running trials in key secondary care conditions such as CNS, oncology, vaccines and NASH with specialist investigators. https://panthera-bio.com/